Minerva Neurosciences Stock Today
| NERV Stock | USD 1.97 0.08 3.90% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Minerva Neurosciences is selling for under 1.97 as of the 18th of February 2025; that is 3.9 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.91. Minerva Neurosciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 1st of March 2023 and ending today, the 18th of February 2025. Click here to learn more.
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. The company has 6.99 M outstanding shares of which 20.9 K shares are now shorted by private and institutional investors with about 0.39 trading days to cover. More on Minerva Neurosciences
Moving against Minerva Stock
Minerva Stock Highlights
| President | MBA FCMA |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Minerva Neurosciences (NERV) is traded on NASDAQ Exchange in USA. It is located in 1500 District Avenue, Burlington, MA, United States, 01803 and employs 9 people. Minerva Neurosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.78 M. Minerva Neurosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 6.99 M outstanding shares of which 20.9 K shares are now shorted by private and institutional investors with about 0.39 trading days to cover.
Minerva Neurosciences currently holds about 40.22 M in cash with (14.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.53, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Minerva Neurosciences Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Minerva Neurosciences is $13.78 Million. Minerva Neurosciences holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Minerva Ownership Details
Minerva Neurosciences Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Minerva Neurosciences market risk premium is the additional return an investor will receive from holding Minerva Neurosciences long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.004 | |||
| Jensen Alpha | (0.04) | |||
| Total Risk Alpha | (0.04) | |||
| Treynor Ratio | (0.05) |
Minerva Stock Against Markets
Minerva Neurosciences Corporate Management
| CPA CPA | CFO VP | Profile | |
| Ramana Kuchibhatla | Senior Development | Profile | |
| FCMA FCMA | President | Profile | |
| William Boni | Vice Communications | Profile |
Additional Tools for Minerva Stock Analysis
When running Minerva Neurosciences' price analysis, check to measure Minerva Neurosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Minerva Neurosciences is operating at the current time. Most of Minerva Neurosciences' value examination focuses on studying past and present price action to predict the probability of Minerva Neurosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Minerva Neurosciences' price. Additionally, you may evaluate how the addition of Minerva Neurosciences to your portfolios can decrease your overall portfolio volatility.